Paul Robbins, DO
Nephrology · Wynnewood, PANPI 1508854506
Payments from drug & device makers
Across 44 payments — averaging $27.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$244
- Bayer$190
- Scpharmaceuticals Inc.$143
- Novartis$123
- AstraZeneca$69
- Shield Therapeutics Inc$60
- plus $366 from 10 others
What the payments were for
- Food & beverage$1,193100%
- Education$20%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 12 | $244 |
| Bayer | 3 | $190 |
| Scpharmaceuticals Inc. | 5 | $143 |
| Novartis | 4 | $123 |
| AstraZeneca | 3 | $69 |
| Shield Therapeutics Inc | 1 | $60 |
| Aurinia Pharma U.S., Inc. | 2 | $59 |
| Travere Therapeutics, Inc. | 3 | $55 |
| Cormedix Inc. | 2 | $55 |
| Boehringer Ingelheim | 2 | $51 |
| Fresenius USA Marketing, Inc. | 2 | $30 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Calliditas Therapeutics US Inc. | 1 | $26 |
| Apellis Pharmaceuticals, Inc. | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Vifor Pharma, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$122
How this compares
$1,195 in reported general payments places this provider in the 60th percentile of 586 nephrology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 11 | $8,307 |
| Calcium Acetate | 22 | $1,358 |
| Sevelamer Carbonate | 13 | $1,179 |
| Nifedipine ErNifedipine | 37 | $791 |
| Cinacalcet Hcl | 13 | $766 |
| Mycophenolate Mofetil | 16 | $637 |
| Carvedilol | 45 | $504 |
| Calcitriol | 32 | $482 |
| Amlodipine Besylate | 44 | $432 |
| Famotidine | 69 | $386 |
| Valsartan | 30 | $368 |
| Hydralazine Hcl | 33 | $367 |
| Losartan Potassium | 28 | $311 |
| Tamsulosin Hcl | 20 | $294 |
| Gentamicin Sulfate | 12 | $258 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Wynnewood
- Geoffrey TeehanWynnewood$72K
- Katalin SusztakPhiladelphia$4.8M
- Debbie Cohen SteinPhiladelphia$2.8M
- Nelson KopytAllentown$2.1M
- Iris LeePhiladelphia$1.9M
- Abdallahsassine GearaPhiladelphia$1.2M
- Alexander ChangDanville$1000K
- Gaia MuallemPhiladelphia$942K
- Chike OkechukwuUpland$875K
- Christopher GislerPittsburgh$757K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.